Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5454241 | 1.00 | GABRA1 (0.43) | GABRA1GABRB2HPGDKMT2AMEN1 | |
| SCHEMBL6806734 | 0.81 | GABRA1 (0.49) | GABRA1GABRB2HPGDKMT2AMEN1 | |
| SCHEMBL533868 | 0.78 | SMN1; SMN2 (0.55) | HPGDKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2010954 | 0.78 | SMN1; SMN2 (0.55) | HPGDKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL533867 | 0.78 | SMN1; SMN2 (0.55) | HPGDKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5226691 | 0.77 | ALDH1A1 (0.57) | GABRA1GABRB2HPGDKMT2AMEN1 | |
| SCHEMBL1908482 | 0.73 | GABRA1 (0.66) | GABRA1GABRB2HPGDKMT2AMEN1 | |
| SCHEMBL248573 | 0.72 | PNMT (0.56) | GABRA1GABRB2HPGDALDH1A1TAAR1 | |
| SCHEMBL22790136 | 0.72 | LIPG (0.44) | KMT2AMEN1SMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL20237769 | 0.72 | ALDH1A1 (0.53) | KMT2AMEN1ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197393-A1 | TRICYCLIC BENZOYLPYRAZOLE DERIVATIVES | WITSCHEL MATTHIAS | 2007-08-23 | — | — | US | disclosed |
| EP-1163240-B1 | TRICYCLIC BENZOYLPYRAZOLE DERIVATIVES USED AS A HERBICIDE | BASF AG (DE) | 2007-03-14 | — | — | EP | disclosed |
| US-7115545-B1 | Tricyclic benzoylpyrazole derivatives used as a herbicide | BASF AKTIENGESELLSCHAFT (DE) | 2006-10-03 | — | — | US | disclosed |
| EP-1181295-B1 | TRICYCLIC BENZOYLCYCLOHEXANEDIONE DERIVATIVES | BASF AG (DE) | 2004-02-18 | — | — | EP | disclosed |
| US-6583089-B1 | Pre- and postemergence herbicides such as (5,5-dimethyl-1,3-dioxocyclohex-2yl)(6-methoxy-3a,4-dihydro-3H -chromeno(4,3c) isoxazolin-9-yl)methanone, formed by acylation and rearranging in the presence of catalysts | BASF AKTIENGESELLSCHAFT (DE) | 2003-06-24 | — | — | US | disclosed |
| CN-1358186-A | Tricyclic benzoylcylohexanedione derivatives | BASF AG (DE) | 2002-07-10 | — | — | CN | disclosed |
| EP-1181295-A2 | TRICYCLIC BENZOYLCYCLOHEXANEDIONE DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2002-02-27 | — | — | EP | disclosed |
| EP-1163240-A1 | TRICYCLIC BENZOYLPYRAZOLE DERIVATIVES USED AS A HERBICIDE | BASF AKTIENGESELLSCHAFT (DE) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000073311-A2 | TRICYCLIC BENZOYLCYCLOHEXANEDIONE DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2000-12-07 | — | — | WO | disclosed |
| WO-2000055158-A1 | TRICYCLIC BENZOYLPYRAZOLE DERIVATIVES USED AS A HERBICIDE | BASF AKTIENGESELLSCHAFT (DE) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197393-A1 | TRICYCLIC BENZOYLPYRAZOLE DERIVATIVES | CBR3, CBR1, KAT8 | GABRA1 571/4885GABRB2 631/4885HPGD 3690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.